Literature DB >> 20155852

Immaturity associated antigens are lost during induction for T cell lymphoblastic leukemia: implications for minimal residual disease detection.

Mikhail Roshal1, Jonathan R Fromm, Stuart Winter, Kimberly Dunsmore, Brent L Wood.   

Abstract

BACKGROUND: Induction chemotherapy for acute leukemia often leads to antigenic shifts in residual abnormal blast populations. Studies in precursor B cell ALL (B-ALL) have demonstrated that chemotherapy commonly results in the loss of antigens associated with immaturity, limiting their utility for minimal residual disease (MRD) detection. Little information is available about the stability of these antigens in precursor T cell ALL (T-ALL) though it is presumed that CD99 and terminal deoxynucleotidyl transferase (TdT) are highly informative based on limited studies.
METHODS: In a longitudinal investigation, we explored patterns of lineage specific and immaturity-associated antigens in T-ALL in a large cohort of patients treated under the multicenter Children's Oncology Group (COG) protocol. All samples were analyzed using multicolor flow cytometry in a standardized fashion at a single institution.
RESULTS: We report that markers of immaturity particularly, TdT and CD99, dramatically decline on leukemic blasts during therapy. CD34 and CD10 expression is confined to a minority of pretreatment samples and is also not stable. In contrast, lineage-associated markers including CD2, CD3, CD4, CD5, CD7, and CD8 failed to show significant trends.
CONCLUSIONS: Our study strongly argues for expansion of immunophenotyping panels for T-ALL MRD to decrease reliance on immature antigens. This study represents the first demonstration of consistent immunophenotypic shifts in T-ALL. 2010 Clinical Cytometry Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20155852      PMCID: PMC3025860          DOI: 10.1002/cyto.b.20511

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  29 in total

1.  BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation.

Authors:  P Lucio; G Gaipa; E G van Lochem; E R van Wering; A Porwit-MacDonald; T Faria; E Bjorklund; A Biondi; M W van den Beemd; E Baars; B Vidriales; A Parreira; J J van Dongen; J F San Miguel; A Orfao
Journal:  Leukemia       Date:  2001-08       Impact factor: 11.528

Review 2.  Flow cytometry in the diagnosis of acute leukemia.

Authors:  E G Weir; M J Borowitz
Journal:  Semin Hematol       Date:  2001-04       Impact factor: 3.851

3.  Terminal deoxynucleotidyl transferase-negative acute lymphoblastic leukemia.

Authors:  J Faber; H Kantarjian; M W Roberts; M Keating; E Freireich; M Albitar
Journal:  Arch Pathol Lab Med       Date:  2000-01       Impact factor: 5.534

4.  BIOMED-1 concerted action report: flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL).

Authors:  A Porwit-MacDonald; E Björklund; P Lucio; E G van Lochem; J Mazur; A Parreira; M W van den Beemd; E R van Wering; E Baars; G Gaipa; A Biondi; J Ciudad; J J van Dongen; J F San Miguel; A Orfao
Journal:  Leukemia       Date:  2000-05       Impact factor: 11.528

5.  Shifts in expression of cell membrane phenotypes in childhood lymphoid malignancies at relapse.

Authors:  L Borella; J T Casper; S J Lauer
Journal:  Blood       Date:  1979-07       Impact factor: 22.113

6.  High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361).

Authors:  M R Baer; C C Stewart; R K Dodge; G Leget; N Sulé; K Mrózek; C A Schiffer; B L Powell; J E Kolitz; J O Moore; R M Stone; F R Davey; A J Carroll; R A Larson; C D Bloomfield
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

7.  Shifts in expression of immunological cell markers in relapsed acute leukemia.

Authors:  A Tomová; O Babusíková
Journal:  Neoplasma       Date:  2001       Impact factor: 2.575

8.  A human thymus-leukemia antigen defined by hybridoma monoclonal antibodies.

Authors:  R Levy; J Dilley; R I Fox; R Warnke
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

9.  CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease.

Authors:  M N Dworzak; G Fröschl; D Printz; L De Zen; G Gaipa; R Ratei; G Basso; A Biondi; W-D Ludwig; H Gadner
Journal:  Leukemia       Date:  2004-04       Impact factor: 11.528

10.  Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia.

Authors:  E R van Wering; A Beishuizen; E T Roeffen; B E van der Linden-Schrever; M A Verhoeven; K Hählen; H Hooijkaas; J J van Dongen
Journal:  Leukemia       Date:  1995-09       Impact factor: 11.528

View more
  17 in total

1.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

Authors:  J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

2.  Terminal deoxynucleotidyl transferase (TdT)-negative T-cell lymphoblastic lymphoma with loss of the T-cell lineage-specific marker CD3 at relapse: a rare entity with an aggressive outcome.

Authors:  Masroor Hassan; Hafez Mohammad Ammar Abdullah; Abdul Wahid; Muhammad Ashraf Qamar
Journal:  BMJ Case Rep       Date:  2018-06-08

3.  Antigenic drift in relapsed extramedullary multiple myeloma: plasma cells without CD38 expression.

Authors:  Prashant Tembhare; Constance Yuan; Neha Korde; Irina Maric; Ola Landgren
Journal:  Leuk Lymphoma       Date:  2011-11-25

4.  Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434.

Authors:  Stuart S Winter; Kimberly P Dunsmore; Meenakshi Devidas; Nancy Eisenberg; Barbara L Asselin; Brent L Wood; Marcia S Leonard Rn; John Murphy; Julie M Gastier-Foster; Andrew J Carroll; Nyla A Heerema; Mignon L Loh; Elizabeth A Raetz; Naomi J Winick; William L Carroll; Stephen P Hunger
Journal:  Pediatr Blood Cancer       Date:  2015-03-08       Impact factor: 3.167

5.  T-ALL Minimal Residual Disease Using a Simplified Gating Strategy and Its Clinico-hematologic Correlation: A Single Center Experience from North India.

Authors:  Neha Singh; Narendra Agrawal; Ridhi Sood; Gayatri Vishwakarma; Dushyant Kumar; Surender Dhanda; Narender Tejwani; Rayaz Ahmed; Dinesh Bhurani; Anurag Mehta
Journal:  Indian J Hematol Blood Transfus       Date:  2019-03-05       Impact factor: 0.900

Review 6.  Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.

Authors:  Franklin Fuda; Weina Chen
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

7.  Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study.

Authors:  Julio C Barredo; Caroline Hastings; Xiamin Lu; Meenakshi Devidas; Yichen Chen; Daniel Armstrong; Naomi Winick; Brent Lee Wood; Rochelle Yanofsky; Mignon Loh; Julie M Gastier-Foster; Dean Thomas Jorstad; Robert Marcus; Kim Ritchey; William L Carrol; Stephen P Hunger
Journal:  Pediatr Blood Cancer       Date:  2017-12-29       Impact factor: 3.167

8.  Detection of minimal residual disease in childhood B-acute lymphoblastic leukemia by 4-color flowcytometry.

Authors:  Ahmad Baraka; Laila M Sherief; Naglaa M Kamal; Shereen El Shorbagy
Journal:  Int J Hematol       Date:  2017-03-21       Impact factor: 2.490

Review 9.  Flow Cytometric Minimal Residual Disease Analysis in Acute Leukemia: Current Status.

Authors:  Pulkit Rastogi; Man Updesh Singh Sachdeva
Journal:  Indian J Hematol Blood Transfus       Date:  2019-04-02       Impact factor: 0.900

10.  Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG).

Authors:  Sumit Gupta; Meenakshi Devidas; Mignon L Loh; Elizabeth A Raetz; Si Chen; Cindy Wang; Patrick Brown; Andrew J Carroll; Nyla A Heerema; Julie M Gastier-Foster; Kimberly P Dunsmore; Eric C Larsen; Kelly W Maloney; Leonard A Mattano; Stuart S Winter; Naomi J Winick; William L Carroll; Stephen P Hunger; Michael J Borowitz; Brent L Wood
Journal:  Leukemia       Date:  2018-02-23       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.